Back to the Pharma Future - The product feast has turned to famine-now where do companies turn? - BioPharm International

ADVERTISEMENT

Back to the Pharma Future
The product feast has turned to famine-now where do companies turn?


BioPharm International


In contrast to 1988, today's pharma marketplace is rife with pricing pressures, generic erosion, and increasing public, political, and regulatory scru-tiny. But, just recognize that the drug drought is the "disease" producing these troubling symptoms, and the cure becomes apparent. An industry that has gradually become reliant on biopharma and other third parties to stock its pipeline must continue to be creative in its business development approaches. Pharma must formulate new business models as well as new products. Its future depends on it.

Stan Bernard, MD and MBA, is president of Bernard Associates LLC, a management consulting firm that provides strategic planning, business development, and marketing services to health- care and pharmaceutical industry clients. He is also a senior fellow at The Wharton School of Business, where he has been teaching Pharmaceutical Management since 1991. Dr. Bernard can be reached at (908) 234-2704 or at
.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here